BRIEF-Biogen To Pause Or Terminate Investment In Majority Of Legacy Apellis Research Programs, Says Spokesperson

Biogen Inc.

Biogen Inc.

BIIB

0.00

June 26 (Reuters) - Biogen Spokesperson:

  • BIOGEN SPOKESPERSON - CONDUCTING COMPREHENSIVE REVIEW OF FORMER APELLIS CLINICAL PRECLINICAL PORTFOLIO TO FURTHER EVALUATE STRATEGIC FIT

  • BIOGEN SPOKESPERSON: BIOGEN MADE THE DECISION TO PAUSE OR TERMINATE INVESTMENT IN THE MAJORITY OF LEGACY APELLIS RESEARCH PROGRAMS

  • BIOGEN SPOKESPERSON: A SMALL NUMBER OF ROLES WITHIN THE RESEARCH ORGANIZATION HAVE BEEN ELIMINATED


Further company coverage: BIIB.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.